patients with clinical edema and grade 2 induration, mean difference in dermis thickness was 1.61 mm (0.27 - 2.95, p<0.03). Edema was associated with a more diffuse signal and an indistinct demarcation against the subcutaneous tissue. This was more pronounced in the lower quadrants (Figure).

**Conclusion:** High-frequency US has potential to measure increased dermis thickness associated with radiation-induced induration in breast cancer patients. Edema may increase dermis thickness and lead to a more diffuse US signal.

High-resolution ultrasound images of two patients without and with edema. Both have grade 2 fibrosis.

**EP-1156**

**Radiotherapy for ductal carcinoma in situ: patterns of recurrence and risk factors stratification**

I. Meattini 1, L. Livi 2, P. Bastiani 3, V. Scotti 2, L. Paolotti 2, C. De Luca Cardillo 1, R. Barca 1, D. Greto 1, F. Martella 1, G. Simonacchi 1, G. Tinacci 1, J. Nori 4, H. Smith 1, L. Sanchez 1, L. Galli 2, L. Orzalesi 2, S. Fondelli 2, S. Bianchi 2, F. Rossi 2

1 Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit - University of Florence, Florence, Italy
2 S. Maria Annunziata Hospital, Radiation Oncology Unit, Florence, Italy
3 Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Florence, Italy
4 Azienda Ospedaliero-Universitaria Careggi, Pathology Unit - University of Florence, Florence, Italy

**Purpose or Objective:** Ductal carcinoma in situ (DCIS) represents around 20% of breast cancers (BC). Standard treatment after breast conserving surgery is still adjuvant radiotherapy (RT). Several randomized trials and meta-analysis showed a 50% risk reduction in LR after adjuvant RT. The aim of our analysis was to evaluate the LR rate and possibly to identify a risk groups stratification for DCIS treatment optimization.

**Material and Methods:** We analyzed 457 patients that underwent BCS and adjuvant RT between 1990 and 2012. Median dose to the whole breast was 50 Gy in 25 fractions; patients with positive/close final surgical margins received a tumor bed boost. We stratified patients in low risk group using well known risk factor for LR (n=203; age<60 years, surgical margins ≥10 mm, nuclear grade 1-2, pT<25 mm), and intermediate-high risk group (n=254; age≥50 years, surgical margins <10 mm, nuclear grade 3 or pT >25 mm). We performed also a patient stratification according to Van Nuys Prognostic Index. Estrogen and progesterone receptors status, nuclear grade, and Ki-67 proliferative index were available for most patients.

**Results:** The mean age was 57 years (range 33-80). Hormonal status was positive in 92% of patients, 83 cases (18.2%) received adjuvant endocrine therapy. All patients received postoperative RT, 198 cases (43%) received also a RT boost on tumor bed.

At a median follow up time of 12 years (range 3-23), we observed 26 LR (5.6%). Following risk groups stratification, we observed seven LR (3.4%) in low risk group and nineteen LR (7.4%) in intermediate-high risk group (p=0.001).

**Conclusion:** Our experience evidenced a significant difference in LR incidence after adjuvant RT based on our risk factors stratification.

This confirms the wide heterogeneity of DCIS. Identification of clear subgroups of patients following risk factors is still lacking. Waiting for results from ongoing clinical phase 3 trials and genomic studies, postoperative RT still remains a mainstay in adjuvant treatment for DCIS.

**EP-1157**

**Abstract withdrawn**

**EP-1158**

**Should breathing adapted radiation therapy also be applied for right-sided breast irradiation?**

M. Essers 1, P.M. Poortmans 2, K. Verschueren 3, S. Hol 4, D.C. Cobben 4

1 Dr. Bernard Verbeeten Instituut, Department of Medical Physics, Tilburg, The Netherlands
2 Radboud University Medical Centre, Radiation Oncology, Nijmegen, The Netherlands
3 Dr. Bernard Verbeeten Instituut, Radiation Oncology, Tilburg, The Netherlands

**Purpose or Objective:** Voluntary moderate deep inspiration breath-hold (vmDIBH) is widely used for patients with left-sided breast cancer. The purpose of this study was to investigate the utility of vmDIBH in local and locoregional radiation therapy (RT) for patients with right-sided breast cancer.

**Material and Methods:** For fourteen patients with right-sided breast cancer, forward IMRT plans were calculated on free-breathing (FB) and vmDIBH CT-scans, for local- as well as locoregional breast treatment, with and without internal mammary lymph nodes (IMN). We compared dose volume parameters to estimate the reduction in the risk of radiation pneumonitis, the influence on pulmonary lung function tests and the risk of secondary lung cancer with the use of vmDIBH.

**Results:** For local breast treatment, no relevant reduction in mean lung dose (MLD) was found. For locoregional breast treatment without IMN, the average MLD reduced from 6.5 to 5.4 Gy (p<0.005) for the total lung and from 11.2 to 9.7 Gy (p<0.005) for the ipsilateral lung. For locoregional breast treatment with IMN, the average MLD reduced from 10.8 to 9.1 Gy (p<0.005) for the total lung and from 18.7 to 16.2 Gy (p<0.005) for the ipsilateral lung. We also found a reduction in mean heart dose between 0.6 and 2.6 Gy in four patients; with a mean of 0.4 Gy for all 14 patients together (p=0.07). We estimate that 1 out of 100 patients will not develop radiation pneumonitis when breath-hold is applied during locoregional right-sided breast cancer treatment. For ever-smoking women, the risk of secondary lung cancer might also be reduced by vmDIBH.

**Conclusion:** Breathing adapted radiation therapy in patients with left-sided breast cancer is becoming widely introduced. As a result of the slight reduction in lung dose found for